On August 1, 2025, Allogene Therapeutics, Inc. announced they will use standard fludarabine and cyclophosphamide (FC) in the ALPHA3 study for large B-cell lymphoma treatments, after closing enrollment on a previous arm due to a serious adverse event. The upcoming milestone, a futility analysis comparing minimal residual disease, is expected in the first half of 2026.